[go: up one dir, main page]

WO2002028351A3 - Proteines recombinantes de liaison a la mucine issues de $i(steptococcus pneumoniae) - Google Patents

Proteines recombinantes de liaison a la mucine issues de $i(steptococcus pneumoniae) Download PDF

Info

Publication number
WO2002028351A3
WO2002028351A3 PCT/US2001/031269 US0131269W WO0228351A3 WO 2002028351 A3 WO2002028351 A3 WO 2002028351A3 US 0131269 W US0131269 W US 0131269W WO 0228351 A3 WO0228351 A3 WO 0228351A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
proteins
mucin binding
recombinant mucin
steptococcus pneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/031269
Other languages
English (en)
Other versions
WO2002028351A2 (fr
WO2002028351A9 (fr
Inventor
Bruce A Green
Amy W Masi
Molakala S Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Research Foundation of the State University of New York
Original Assignee
Wyeth LLC
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC, Research Foundation of the State University of New York filed Critical Wyeth LLC
Priority to AU2002213037A priority Critical patent/AU2002213037A1/en
Publication of WO2002028351A2 publication Critical patent/WO2002028351A2/fr
Publication of WO2002028351A3 publication Critical patent/WO2002028351A3/fr
Publication of WO2002028351A9 publication Critical patent/WO2002028351A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des séquences d'acides aminés et d'acides nucléiques de protéines isolées de liaison à la mucine issues de bactéries pneumococciques et leurs fragments. Elle concerne également des vecteurs d'expression, des cellules hôtes transfectées, des méthodes de production de protéines recombinantes de liaison à la mucine, des compositions contenant ces protéines, et des anticorps inhibant ces protéines. L'invention concerne en outre une méthode pouvant induire une réponse immunitaire, ainsi que des méthodes de criblage et de diagnostic.
PCT/US2001/031269 2000-10-04 2001-10-04 Proteines recombinantes de liaison a la mucine issues de $i(steptococcus pneumoniae) Ceased WO2002028351A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002213037A AU2002213037A1 (en) 2000-10-04 2001-10-04 Recombinant mucin binding proteins from steptococcus pneumoniae

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23788800P 2000-10-04 2000-10-04
US60/237,888 2000-10-04
US26710401P 2001-02-07 2001-02-07
US60/267,104 2001-02-07

Publications (3)

Publication Number Publication Date
WO2002028351A2 WO2002028351A2 (fr) 2002-04-11
WO2002028351A3 true WO2002028351A3 (fr) 2002-07-18
WO2002028351A9 WO2002028351A9 (fr) 2002-12-05

Family

ID=26931135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031269 Ceased WO2002028351A2 (fr) 2000-10-04 2001-10-04 Proteines recombinantes de liaison a la mucine issues de $i(steptococcus pneumoniae)

Country Status (2)

Country Link
AU (1) AU2002213037A1 (fr)
WO (1) WO2002028351A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382970A1 (fr) * 2002-07-15 2004-01-21 Societe Des Produits Nestle S.A. Nouveaux polypeptides capables de se fixer à mucin
EP1394176A1 (fr) * 2002-08-27 2004-03-03 Nestec S.A. Nouveaux polypeptides de liaison de mucin dérivés de Lactobacillus johnsonii
CN109553662B (zh) * 2018-11-02 2021-07-13 宁波大学 一种功能性嗜酸乳杆菌黏液结合蛋白的表达纯化及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006734A1 (fr) * 1996-08-16 1998-02-19 Smithkline Beecham Corporation Nouveaux polynucleotides et polypeptides procaryotes et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006734A1 (fr) * 1996-08-16 1998-02-19 Smithkline Beecham Corporation Nouveaux polynucleotides et polypeptides procaryotes et leurs utilisations

Also Published As

Publication number Publication date
WO2002028351A2 (fr) 2002-04-11
AU2002213037A1 (en) 2002-04-15
WO2002028351A9 (fr) 2002-12-05

Similar Documents

Publication Publication Date Title
IL264925A (en) Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses
WO1998018930A3 (fr) ANTIGENES ET VACCINS ACTIFS CONTRE $i(STREPTOCOCCUS PNEUMONIAE)
WO2001073059A3 (fr) 38692 et 21117, nouvelles molecules de phosphatase a double specificite et leurs utilisations
WO2001031019A3 (fr) Peptides antigeniques de neisseria
WO2000052047A3 (fr) Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations
WO2000019988A8 (fr) NOUVELLES MOLECULES SPECIFIQUES DE Th2 ET LEURS UTILISATIONS
WO2001075112A3 (fr) Antigene chlamydia, fragments d'adn correspondants, et leurs utilisations
WO2001061005A3 (fr) Nouvelles molecules de la famille de proteines du domaine pyrine, et leurs utilisations
WO2002028351A3 (fr) Proteines recombinantes de liaison a la mucine issues de $i(steptococcus pneumoniae)
WO2001075114A3 (fr) Antigenes de $i(chlamydia) et fragments d'adn correspondants, et leur utilisation
WO2001092493A3 (fr) Nouvelles aminopeptidases humaines 21956 et 25856, et utilisations
WO2002061049A3 (fr) Nouvelles molecules de la famille des proteines pyrin/nbs/lrr et leurs utilisations
WO2001018216A3 (fr) Nouvelle protease calpaine 26176 et utilisations
WO2000008045A3 (fr) Nouvelles molecules de la famille de proteines apparentees a tango-93 et leurs utilisations
WO2003029434A3 (fr) Nouvelles molecules de la famille de proteines associee a la hkid-1 et utilisations desdites molecules
WO2002000859A3 (fr) 46508 nouveau membre humain de la famille des peptidyl-arnt hydrolases et ses utilisations
WO2001077151A3 (fr) Nouvelles molecules de proteines et d'acide nucleique fdrg et utilisation desdites molecules
WO2002074960A3 (fr) Methodes et compositions relatives aux proteines humaines 38650, 28472, 5495, 65507, 81588 et 14354 et leurs utilisations
WO2002046408A3 (fr) Nouvelles proteines humaines, polynucleotides les codant et procedes d'utilisation
WO2000043419A3 (fr) Proteine de voies d'exocytose et leurs procedes d'utilisation
WO1998002557A3 (fr) Fnt-alpha convertase mammalienne
WO2001083752A3 (fr) 23949 et 32391, nouveaux canaux ioniques humains, et utilisation associee
WO1999062943A3 (fr) Nouvelles molecules de la famille des proteines apparentees aip et leurs utilisations
WO2001083753A3 (fr) Nouvelles molecules appartenant a la famille de proteines nbs/lrr et utilisations de ces dernieres
WO2002081629A3 (fr) Nouvelles proteines humaines, polynucleotides codant celles-ci et procede d'utilisation de ceux-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP